Naftidrofuryl oxalate improves impaired brain glucose metabolism after microsphere-induced cerebral embolism in rats. 1991

S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
Department of Pharmacology, Tokyo College of Pharmacy, Japan.

The present study was designed to elucidate possible therapeutic effects of naftidrofuryl on the brain glucose metabolism after cerebral ischemia. Cerebral ischemia was induced by injecting 680 microspheres with a diameter of 48 microns into the right internal carotid artery of the rat. After ensuring the onset of symptoms of stroke on the first day after the operation, the rats were treated with intraperitoneal injections of 15 mg/kg naftidrofuryl oxalate twice a day. The behavioral and metabolic changes of operated rats were monitored up to the 5th day after surgery. The symptoms gradually faded away, from the 3rd day on, after microsphere-induced cerebral embolism. Tissue glucose and glycogen greatly increased after cerebral embolism, suggesting embolism-induced inhibition of glycolysis. To elucidate which steps in the glycolytic catabolism are inhibited after cerebral ischemia, biochemical activities of the glycolytic enzymes in the Embden-Meyerhof pathway and tricarboxylic acid cycle were determined on the 3rd day after surgery. Enzyme activities of hexokinase, phosphofructokinase and pyruvate kinase were not inhibited, but rather increased slightly after cerebral embolism. Malate dehydrogenase activity in the brain mitochondria was markedly increased after microsphere-embolism, whereas other enzyme activities in the tricarboxylic acid cycle were never inhibited by the cerebral embolism. Treatment of naftidrofuryl resulted in an appreciable reverse of the brain glucose and glycogen levels and a substantial recovery of altered enzyme activities to normal levels in the Embden-Meyerhof pathway and tricarboxylic acid cycle.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008863 Microspheres Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers. Latex Beads,Latex Particles,Latex Spheres,Microbeads,Bead, Latex,Beads, Latex,Latex Bead,Latex Particle,Latex Sphere,Microbead,Microsphere,Particle, Latex,Particles, Latex,Sphere, Latex,Spheres, Latex
D009257 Nafronyl A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors. Nafronyloxalate,Naftidrofuryl,Artocoron,Azunaftil,Di-Actane,Dusodril,Gévatran,LS-121,Nafronyl Oxalate,Nafti Von Ct,Nafti-Puren,Nafti-Ratiopharm,Naftifurin Oxalate,Naftilong,Naftilux,Praxilene,Praxilène,Di Actane,LS 121,LS121,Nafti Puren,Nafti Ratiopharm,NaftiRatiopharm,Oxalate, Nafronyl,Oxalate, Naftifurin
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002542 Intracranial Embolism and Thrombosis Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures. Brain Embolism and Thrombosis,Cerebral Embolism and Thrombosis,Embolism and Thrombosis, Brain
D002560 Cerebrovascular Circulation The circulation of blood through the BLOOD VESSELS of the BRAIN. Brain Blood Flow,Regional Cerebral Blood Flow,Cerebral Blood Flow,Cerebral Circulation,Cerebral Perfusion Pressure,Circulation, Cerebrovascular,Blood Flow, Brain,Blood Flow, Cerebral,Brain Blood Flows,Cerebral Blood Flows,Cerebral Circulations,Cerebral Perfusion Pressures,Circulation, Cerebral,Flow, Brain Blood,Flow, Cerebral Blood,Perfusion Pressure, Cerebral,Pressure, Cerebral Perfusion
D002952 Citric Acid Cycle A series of oxidative reactions in the breakdown of acetyl units derived from GLUCOSE; FATTY ACIDS; or AMINO ACIDS by means of tricarboxylic acid intermediates. The end products are CARBON DIOXIDE, water, and energy in the form of phosphate bonds. Krebs Cycle,Tricarboxylic Acid Cycle,Citric Acid Cycles,Cycle, Citric Acid,Cycle, Krebs,Cycle, Tricarboxylic Acid,Cycles, Citric Acid,Cycles, Tricarboxylic Acid,Tricarboxylic Acid Cycles
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006003 Glycogen

Related Publications

S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
February 1994, Arzneimittel-Forschung,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
May 1994, British journal of pharmacology,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
June 1995, Stroke,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
May 2000, Nephron,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
February 1998, Brain research,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
October 1996, Brain research,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
October 1998, Brain research,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
March 1993, Stroke,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
May 2009, Journal of neurochemistry,
S Takeo, and R Tanonaka, and K Miyake, and K Tanonaka, and T Taguchi, and K Kawakami, and M Ono, and M Hiramatsu, and K Okano
January 1984, Arzneimittel-Forschung,
Copied contents to your clipboard!